 |
|
 |
| On Friday, 25
October 2013, the 8th Hanseatic India Colloquium started
with the Opening Session and Words of Greetings by Mr. Stefan
Matz, Director International Department, HWF Hamburg Business
Development Cooperation. HWF was part of the Organization
Team of the Colloquium. |
|
Dr. Hinrich
Habeck, Managing Director of Norgenta North German Life Science
Agency, Hamburg, gave the Welcome Address. Norgenta was also
part of the Organization Team of the Colloquium. |
 |
|
 |
| The
Honourable Consul General of India in Hamburg, Dr. Vidhu
P. Nair, presented the Opening Address. |
|
Dr.
Amal Mukhopadhyay, Founder and Director, ELGA Biotech, Hamburg,
and convenor of the Colloquium, was the chairman of Session
I. |
 |
|
 |
| Dr.
Björn Windshügel, Head of Bioinformatics, European Screening
Port, Hamburg, described a model for Indo-German collaboration
in R & D. |
|
Mr.
Vimalendu K. Singh, Chief Executive Global Generics, RPG
Life Sciences
Ltd., Mumbai,
spoke about generics in healthcare and the opportunities
offered by India. |
 |
|
 |
| When the speakers
had finished their presentations
the audience had the opportunity for questions
and discussions. |
|
Prof. Dr. Rainer
Böger, Managing Director, Clinical Trial Center North,
Hamburg, gave a lecture on clinical research as a fundamental
component of drug discovery. |
 |
|
 |
| Coffeebreak
was used for networking ... |
|
... and interesting
discussions. |
 |
|
 |
| In
Session II Dr. Vijay K. Shastri, Technical Director, Murli
Krishna Pharma Pvt. Ltd., Pune, described the Indian scenario
of generic drug development. |
|
Dr.
Antony Raj Gomas, Sr. Vice Pesident - Quality, Mylan Laboratories,
Hyderabad, spoke about API manufacturing in India |
 |
|
 |
| A
view of the audience |
|
Dr.
Stefanie Greifeneder, Partner Munich, Field Fisher Waterhouse
LLB,
gave a presentation on legal challenges for transnational
co-operations in drug development and clinical research..
|
 |
|
 |
| The
lunch-break gave the opportunity for a lot of interesting
discussions. |
|
Dr.
Amal Mukhopadhyay (M), Mr. Dieter Grützmacher (R), CEO MCC
Marketing Concept Consulting Administration GmbH and Co-organizer,
together with Mr. Matthias C. Lischke (L), Economic Affairs
Council, Hamburg. |
 |
|
 |
| Dr. Harm Peters,
Managing Director, AET Biotechnologie GmbH, was the first
speaker in Session III and gave an overview of 50 years of
generic experience. |
|
Mrs. Satya R.
Vadlamani, Chief Managing Director, Murli Krishna Pharma
Pvt. Ltd., Pune,,
spoke about scaling business to the next level - pharmaceutical
industry. |
 |
|
 |
| Mr. Federico
Pollano, Managing Director, Richter-Helm Biotec GmbH & Co
KG, Hamburg, described his company as a global partner
for Biotechnology and Biosimilars. |
|
Dr. Wolfram
Altenhofen, Vice President Business Development, AET Biotechnologie
GmbH, Hamburg, reported on extending business from small
molecules to biologics. |
 |
|
 |
| Subsequent to
the 8th Hanseatic India Colloquium the speakers and participants
again took the opportunity for networking and discussing
potential collaborations. |
|
The 8th Hanseatic
India Colloquium again achieved sustained success and resulted
in a great many of sales activities and collaborations. The
event has been well-received by speakers and partiicipants
and they all request a continuation next year. |
| |
|
|
